Literature DB >> 12713636

Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors.

L M Marubio1, A M Gardier, S Durier, D David, R Klink, M M Arroyo-Jimenez, J M McIntosh, F Rossi, N Champtiaux, M Zoli, J-P Changeux.   

Abstract

The mesostriatal dopaminergic system influences locomotor activity and the reinforcing properties of many drugs of abuse including nicotine. Here we investigate the role of the alpha4 nicotinic acetylcholine receptor (nAChR) subunit in mediating the effects of nicotine in the mesolimbic dopamine system in mice lacking the alpha4 subunit. We show that there are two distinct populations of receptors in the substantia nigra and striatum by using autoradiographic labelling with 125I alpha-conotoxin MII. These receptors are comprised of the alpha4, beta2 and alpha6 nAChR subunits and non-alpha4, beta2, and alpha6 nAChR subunits. Non-alpha4 subunit-containing nAChRs are located on dopaminergic neurons, are functional and respond to nicotine as demonstrated by patch clamp recordings. In vivo microdialysis performed in awake, freely moving mice reveal that mutant mice have basal striatal dopamine levels which are twice as high as those observed in wild-type mice. Despite the fact that both wild-type and alpha4 null mutant mice show a similar increase in dopamine release in response to intrastriatal KCl perfusion, a nicotine-elicited increase in dopamine levels is not observed in mutant mice. Locomotor activity experiments show that there is no difference between wild-type and mutant mice in basal activity in both habituated and non-habituated environments. Interestingly, mutant mice sustain an increase in cocaine-elicited locomotor activity longer than wild-type mice. In addition, mutant mice recover from depressant locomotor activity in response to nicotine at a faster rate. Our results indicate that alpha4-containing nAChRs exert a tonic control on striatal basal dopamine release, which is mediated by a heterogeneous population of nAChRs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12713636     DOI: 10.1046/j.1460-9568.2003.02564.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  88 in total

1.  Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration.

Authors:  Olivier George; Allison Lloyd; F Ivy Carroll; M Imad Damaj; George F Koob
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

Review 2.  From smoking to lung cancer: the CHRNA5/A3/B4 connection.

Authors:  M R D Improgo; M D Scofield; A R Tapper; P D Gardner
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

3.  Partial agonists for α4β2 nicotinic receptors stimulate dopaminergic neuron firing with relatively enhanced maximal effects.

Authors:  Ying Chen; Lisa M Broad; Keith G Phillips; Ruud Zwart
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

5.  Comparative effects of dextromethorphan and dextrorphan on nicotine discrimination in rats.

Authors:  M Jerry Wright; Robert E Vann; Thomas F Gamage; M Imad Damaj; Jenny L Wiley
Journal:  Pharmacol Biochem Behav       Date:  2006-11-16       Impact factor: 3.533

6.  Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.

Authors:  H Rollema; A Shrikhande; K M Ward; F D Tingley; J W Coe; B T O'Neill; E Tseng; E Q Wang; R J Mather; R S Hurst; K E Williams; M de Vries; T Cremers; S Bertrand; D Bertrand
Journal:  Br J Pharmacol       Date:  2010-03-22       Impact factor: 8.739

Review 7.  New insights into the genetics of addiction.

Authors:  Ming D Li; Margit Burmeister
Journal:  Nat Rev Genet       Date:  2009-04       Impact factor: 53.242

Review 8.  Pharmacogenetics and smoking cessation with nicotine replacement therapy.

Authors:  Riju Ray; Robert A Schnoll; Caryn Lerman
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

9.  Localized low-level re-expression of high-affinity mesolimbic nicotinic acetylcholine receptors restores nicotine-induced locomotion but not place conditioning.

Authors:  Y S Mineur; D H Brunzell; S R Grady; J M Lindstrom; J M McIntosh; M J Marks; S L King; M R Picciotto
Journal:  Genes Brain Behav       Date:  2008-12-11       Impact factor: 3.449

10.  Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-containing nicotinic receptors.

Authors:  Staci E Engle; J Michael McIntosh; Ryan M Drenan
Journal:  Neuropharmacology       Date:  2014-12-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.